Evidence map›Paper›PMID 37030590›Full record

ArticleThe Journal of allergy and clinical immunology2023

IgG:FcγRIIb signals block effector programs of IgE:FcεRI-activated mast cells but spare survival pathways.

Cynthia Kanagaratham, Tahereh Derakhshan, Yasmeen S El Ansari, Kameryn N Furiness, Eleanor Hollers, Mats Keldsen, Hans C Oettgen, Daniel F Dwyer

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of allergy and clinical immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. IgG:FcγRIIb Signaling on Mast Cells Blocks Allergic Airway Inflammation.International journal of molecular sciences · 2025
    Article
  3. Review
  4. Whence and wherefore IgE?Immunological reviews · 2024
    Review
  5. Feast for thought: A comprehensive review of food allergy 2021-2023.The Journal of allergy and clinical immunology · 2024
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Cynthia KanagarathamDepartment of Pediatrics, Boston Children's Hospital, Boston, Mass; Department of Pediatrics, Harvard Medical School, Boston, Mass.
Tahereh DerakhshanDivision of Allergy and Clinical Immunology, Jeff and Penny Vinik Center for Allergic Disease Research, Brigham and Women's Hospital, Boston, Mass; Department of Medicine, Harvard Medical School, Boston, Mass.
Yasmeen S El AnsariDepartment of Pediatrics, Boston Children's Hospital, Boston, Mass; Institute of Laboratory Medicine, Philipps University Marburg, Marburg, Germany.
Kameryn N FurinessDepartment of Pediatrics, Boston Children's Hospital, Boston, Mass.
Eleanor HollersDivision of Allergy and Clinical Immunology, Jeff and Penny Vinik Center for Allergic Disease Research, Brigham and Women's Hospital, Boston, Mass.
Mats KeldsenDepartment of Pediatrics, Boston Children's Hospital, Boston, Mass.
Hans C OettgenDepartment of Pediatrics, Boston Children's Hospital, Boston, Mass; Department of Pediatrics, Harvard Medical School, Boston, Mass. Electronic address: hans.oettgen@childrens.harvard.edu.
Daniel F DwyerDivision of Allergy and Clinical Immunology, Jeff and Penny Vinik Center for Allergic Disease Research, Brigham and Women's Hospital, Boston, Mass; Department of Medicine, Harvard Medical School, Boston, Mass. Electronic address: dfdwyer@bwh.harvard.edu.
Boston Children's Hospital · USBrigham and Women's Hospital · US

Funding

Mast cell regulation of Th2 induction and tolerance breakdown in food allergyR01AI119918 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI OETTGEN, HANS C · 2015 to 2025
$5.6M
Oxysterol Regulation of Mast Cell BiologyK22AI146281 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI DWYER, DANIEL F · 2020 to 2021
$269k
NIAID NIH HHS K22 AI146281NIAID NIH HHS R01 AI119918
6 · The paper itself

Abstract

backgroundIgE-induced mast cell (MC) degranulation can be inhibited by IgG antibodies, signaling via FcγRIIb, but the effects of IgG on IgE-induced MC transcription are unknown.

objectiveWe sought to assess inhibitory IgG:FcγRIIb effects on MC responses to IgE using complementary transcriptomic and functional approaches.

methodsRNA sequencing was performed on bone marrow-derived MCs from wild-type and FcγRIIb-deficient mice to identify genes activated following IgE receptor crosslinking that were further modulated in the presence of antigen-specific IgG in an FcγRIIb-dependent fashion. Parallel analyses of signaling pathways and allergic responses in vivo were performed to assess the impact of these changes in gene expression.

resultsRapid changes in the transcription of 879 genes occurred in MCs activated by IgE, peaking at 1 hour. Surprisingly, only 12% of these were altered by IgG signaling via FcγRIIb, including numerous transcripts involved in orchestrating type 2 responses linked to spleen tyrosine kinase signaling. Consistent with this finding, IgG suppressed IgE-induced phospho-intermediates in the spleen tyrosine kinase signaling pathway. In vivo studies confirmed that the IgG-mediated suppression of both systemic anaphylaxis and MC-driven tissue recruitment of inflammatory cells following allergen challenge was dependent on FcγRIIb. In contrast, genes in the STAT5a cell survival pathway were unaltered by IgG, and STAT5a phosphorylation increased after IgE-induced MC activation but was unaffected by IgG.

conclusionsOur findings indicate that inhibitory IgG:FcγRIIb signals block an IgE-induced proallergic program but spare a prosurvival program.

Indexed as

AnaphylaxisReceptors, IgEAnimalsCell DegranulationImmunoglobulin EImmunoglobulin GMast CellsMiceReceptors, IgGSyk KinaseImmunoglobulin EImmunoglobulin GReceptors, IgEReceptors, IgGSyk KinaseanaphylaxisFcγRIIbFcεRIIgEIgGmast cellsRNA sequencing

Identifiers

PMID37030590
PMCPMC10524869
OpenAlexW4362673412

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.